For many of us, the medicine cabinet is a sanctuary of health—a place where we find the relief we need for allergies, anxiety, or chronic pain. However, as a physician and journalist, I have spent years observing a challenging paradox in modern medicine: the very treatments we use to manage our daily quality of life can sometimes carry long-term costs that aren’t immediately apparent. One of the most concerning areas of research in recent years involves the link between certain common prescriptions and the increased risk of cognitive decline.
The conversation around dementia has shifted from viewing it as an inevitable part of aging to understanding it as a condition influenced by a complex interplay of genetics, lifestyle, and environmental factors. Among these, the “anticholinergic burden”—the cumulative effect of medications that block acetylcholine, a vital neurotransmitter for memory and learning—has emerged as a critical point of concern for public health experts. When we talk about medications that increase dementia risk, we are not suggesting that these drugs cause dementia in every patient, but rather that long-term or high-dose use may accelerate the progression of cognitive impairment or increase the likelihood of developing the disease.
Understanding these risks is not about fostering fear or encouraging patients to abruptly stop their treatments. In fact, doing so can be dangerous. Instead, it is about fostering a collaborative relationship between patients and their healthcare providers to optimize “deprescribing”—the planned and supervised process of reducing or stopping medications that may no longer be beneficial or may be causing harm. By identifying high-risk drug classes, we can move toward a more personalized approach to brain health that balances immediate symptom relief with long-term neurological preservation.
The Anticholinergic Burden: Blocking the Brain’s Messenger
The most significant class of medications associated with cognitive decline is the anticholinergics. These drugs work by blocking acetylcholine, a chemical messenger in the brain that is essential for the functions of memory, attention, and learning. In patients with Alzheimer’s disease, acetylcholine levels are already naturally depleted; introducing medications that further block this neurotransmitter can lead to acute confusion or a faster decline in cognitive function.
Anticholinergic agents are surprisingly common and are found in a wide array of prescriptions and over-the-counter products. They are frequently used to treat overactive bladder, COPD, and certain types of depression. Common examples include diphenhydramine (found in many sleep aids and allergy medications) and oxybutynin (used for bladder control). Research has consistently shown that a high “anticholinergic burden”—meaning the use of multiple drugs with these properties—is linked to a higher risk of developing dementia over time according to studies indexed by the National Library of Medicine.
The impact is often most visible in older adults, whose brains are more susceptible to the effects of these drugs. Symptoms of anticholinergic toxicity can be subtle, beginning with dry mouth, blurred vision, or constipation, but progressing to “brain fog,” disorientation, and memory lapses. For a patient already in the early stages of mild cognitive impairment (MCI), these medications can push them toward a clinical diagnosis of dementia much faster than would have occurred otherwise.
Benzodiazepines and the Trade-off for Sleep
Benzodiazepines—a class of psychoactive drugs used to treat anxiety and insomnia—represent another area of significant concern. Medications such as diazepam, alprazolam, and lorazepam are highly effective for short-term crisis management or acute insomnia. However, their long-term use has been repeatedly linked to an increased risk of Alzheimer’s disease and other forms of dementia.
The mechanism is complex, but evidence suggests that benzodiazepines may interfere with the brain’s ability to consolidate memories and may disrupt the natural sleep architecture required for the brain to “clear” metabolic waste, including beta-amyloid plaques associated with Alzheimer’s. A large-scale study published in The BMJ indicated that long-term use of benzodiazepines was associated with a significantly higher risk of dementia compared to non-users as detailed in The BMJ archives.
The danger is compounded by the “prescribing cascade.” This occurs when a patient takes a benzodiazepine for sleep, experiences daytime grogginess or cognitive impairment as a side effect, and is then prescribed another medication to treat that secondary symptom. Over years, this accumulation of drugs creates a heavy pharmacological load on the aging brain, making it harder to distinguish between the natural progression of aging and the side effects of medication.
Tricyclic Antidepressants and Antipsychotics
While modern antidepressants, such as SSRIs (Selective Serotonin Reuptake Inhibitors), are generally considered safer for the brain, older classes of medication carry higher risks. Tricyclic antidepressants (TCAs), such as amitriptyline, possess strong anticholinergic properties. While they remain useful for certain types of chronic pain or treatment-resistant depression, their potential to impair cognition makes them a second- or third-line choice for older populations.
Similarly, certain antipsychotic medications used to treat schizophrenia, bipolar disorder, or severe agitation in dementia patients have been linked to an increased risk of stroke and cognitive decline. The FDA has previously issued “black box” warnings for some atypical antipsychotics when used in elderly patients with dementia-related psychosis, noting an increased risk of death and cerebrovascular events per FDA safety communications.
It is important to clarify that for patients with severe psychiatric conditions, the risk of untreated psychosis or profound depression often outweighs the potential long-term risk of cognitive decline. The goal is not the wholesale elimination of these drugs, but rather the use of the lowest effective dose for the shortest possible duration.
The Path Forward: Deprescribing and Brain Health
If you or a loved one are taking medications from these categories, the most important rule is: do not stop taking your medication without consulting your physician. Abruptly stopping benzodiazepines or antidepressants can lead to severe withdrawal symptoms, including rebound anxiety, insomnia, or even seizures.
Instead, I recommend scheduling a “medication review” appointment. This is a dedicated visit where the primary goal is not to treat a fresh symptom, but to audit every single pill, supplement, and over-the-counter drug you are taking. During this review, you can ask your doctor specific questions:
- Is this medication still necessary for my current health status?
- Are there non-pharmacological alternatives (such as Cognitive Behavioral Therapy for insomnia) that could replace this drug?
- Is there a newer medication with a lower anticholinergic profile that would be equally effective?
- If we decide to stop this medication, what is the safest, slowest tapering schedule to avoid withdrawal?
The process of deprescribing is a clinical art. It requires patience and a gradual approach. For example, when tapering a benzodiazepine, a doctor might reduce the dose by a small percentage every few weeks to allow the brain’s GABA receptors to recalibrate. This meticulous process reduces the risk of relapse and minimizes the stress on the central nervous system.
Key Takeaways for Patients and Caregivers
| Medication Class | Common Uses | Primary Cognitive Concern | Action Step |
|---|---|---|---|
| Anticholinergics | Allergies, Bladder Control, COPD | Blocks acetylcholine; impairs memory/learning | Check OTC labels for diphenhydramine |
| Benzodiazepines | Anxiety, Insomnia | Disrupts sleep architecture; linked to Alzheimer’s | Discuss tapering for long-term use |
| Tricyclic Antidepressants | Chronic Pain, Depression | High anticholinergic burden | Explore SSRIs or SNRIs as alternatives |
| Certain Antipsychotics | Psychosis, Severe Agitation | Increased stroke risk in elderly patients | Use lowest effective dose; monitor closely |
The Broader Context: A Holistic Approach to Prevention
While managing medication is vital, it is only one piece of the puzzle. The Lancet Commission on dementia prevention, intervention, and care has highlighted that up to 40% of dementia cases could potentially be delayed or prevented by addressing modifiable risk factors according to the Lancet Commission. These include managing hypertension, treating hearing loss, avoiding smoking, and maintaining social connections.
When we reduce the pharmacological burden on the brain, we create more space for these positive interventions to work. A brain that isn’t clouded by the anticholinergic effects of an allergy pill or the sedative effects of a benzodiazepine is a brain that is better equipped to engage in the physical exercise and social stimulation known to build cognitive reserve.
As an internist, I often tell my patients that the goal of medicine is not just to add years to your life, but to add life to your years. In other words protecting the essence of who we are—our memories, our personality, and our cognitive independence. By being proactive about our medication lists and staying informed about the latest neurological research, we can take an active role in safeguarding our brain health for the decades to come.
The next major milestone in this field will be the continued rollout of more precise “anticholinergic scoring” tools in electronic health records, which will allow physicians to see a patient’s total burden in real-time. Until then, the most powerful tool we have is the conversation between a patient and their provider.
Do you or a family member have a complex medication regimen? Have you ever discussed a “medication review” with your doctor? We invite you to share your experiences and questions in the comments below.